Financial Results & Reports - suPARnostic® by ViroGates

Below you can find financial results, reports, presentations, IPO and more. Interim Report, Q3 2020 Click here to download ViroGates' Interim Report Q3 2020 Financial Results, Q3 2020 Annual Report 2019 In 2019, ViroGates achieved many significant milestones, including four new clinical routine customers, a pipeline of +50 hospitals evaluating the implementation of suPAR in clinical routine practice, and validation on all commercially relevant Roche Diagnostics cobas instruments. All these achievements are a result of the company’s core focus on commercializing its suPARnostic® products following the initial public offering in June 2018. Click here to download ViroGates' Annual Report 2019. Previous Annual Reports Annual report 2018 Annual report 2017 Annual report 2016 Annual report 2015 Annual report 2014 Annual report 2013 Annual report 2012 Annual report 2011 Annual report 2010 Previous Interim Reports Interim Report Q2 2020 Interim Report Q1 2020 Interim Report Q3 2019 Interim Report Q2 2019 Interim Report Q1 2019 Interim Report Q3 2018 Interim Report Q2 2018 Analyst Reports 2020 6 November 2020: Analyse af ViroGates A/S by Aktieinfo 27 October 2020: Market Focus Update by Västra Hamnen Corporate Finance 14 August 2020: Market Focus Update by Västra Hamnen Corporate Finance 30 March 2020: Market Focus Update by Västra Hamnen Corporate Finance 29 January 2020: Market Focus Initial Research by Västra Hamnen Corporate Finance 2019 12 April 2019: Analyse af ViroGates A/S by Aktieinfo 2018 4 October 2018: Analyse af ViroGates A/S by Aktieinfo IPO 2018 Documents ViroGates Prospectus 2018 (Full version in English) ViroGates Prospectus 2018 (Summary in Swedish) ViroGates Prospectus 2018 Announcement ViroGates Brochure (in Swedish) 11 June 2018: Presentation at Aktiespararnas Småbolagsdag in Stockholm 12 June 2018: Presentation at InvestorDagen by the Danish Shareholders' Association in Aarhus